A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
Latest Information Update: 10 Mar 2025
At a glance
- Drugs AZD-5851 (Primary)
- Indications Liver cancer; Prostate cancer
- Focus Adverse reactions
- Acronyms LOCUS
- Sponsors AstraZeneca
Most Recent Events
- 05 Mar 2025 Planned initiation date changed from 16 Oct 2024 to 17 Sep 2025.
- 04 Jul 2024 Planned initiation date changed from 12 Jun 2024 to 16 Oct 2024.
- 22 Mar 2024 Planned number of patients changed from 30 to 64.